Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Elvin, GB

John Gawain Elvin, Meldreth GB

Patent application numberDescriptionPublished
20090311241Human antibodies that bind human IL-12 and methods for producing - Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention. 12-17-2009

John Elvin, Cambridge GB

Patent application numberDescriptionPublished
20120114652ANTI-PAI-1 ANTIBODIES AND METHODS OF USE THEREOF - Provided are anti-PAI-1 antibodies or antibody fragments and methods of using them.05-10-2012

John Gawain Elvin, Royston GB

Patent application numberDescriptionPublished
20080305114HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING - Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.12-11-2008
20110123544HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING - Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.05-26-2011

John Gawain Elvin, Cambridge GB

Patent application numberDescriptionPublished
20090175857Human Antibodies That Bind Human IL-12 And Methods For Producing - Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.07-09-2009
20090269302HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING - Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.10-29-2009

Paul Elvin, Macclesfield GB

Patent application numberDescriptionPublished
20090123476TARGETED BINDING AGENTS DIRECTED TO UPAR AND USES THEREOF - Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.05-14-2009

Paul Elvin, Cheshire GB

Patent application numberDescriptionPublished
20100233154TARGETED BINDING AGENTS DIRECTED TO HEPARANASE AND USES THEREOF 463 - The invention relates to targeted binding agents that specifically bind to heparanase and inhibit the biological activity of heparanase and uses of such agents. More specifically the invention relates to fully human monoclonal antibodies directed to that specifically bind to heparanase and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The disclosed targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of heparanase.09-16-2010

Paul Elvin, Northwich Cheshire GB

Patent application numberDescriptionPublished
20120108797TARGETED BINDING AGENTS DIRECTED TO UPAR AND USES THEREOF - Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementary determine regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.05-03-2012

Stephen John Elvin, Salisbury GB

Patent application numberDescriptionPublished
20090155295VACCINE - A polypeptide derived from the periplasmic space of 06-18-2009
20090220548Immunogenic Agents Against Burkholderia Psudomallei And/Or Burkholderia Mallei, Comprising Lipopolysaccharide, Capsular Polysaccharide And/Or Proteins From Burkholderia Pseudomallei - An immunogenic agent which comprises a killed strain of 09-03-2009
20110236423IMMUNOGENIC AGENTS AGAINST BURKHOLDERIA PSEUDOMALLEI AND/OR BURKHOLDERIA MALLEI, COMPRISING LIPOPOLYSACCHARIDE, CAPSULAR POLYSACCHARIDE AND/OR PROTEINS FROM BURKHOLDERIA PSEUDOMALLEI - An immunogenic agent which comprises a killed strain of 09-29-2011